Please use this identifier to cite or link to this item:
|Title:||Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.|
|Authors:||Torresi, Joseph;McCarthy, Karen;Feroldi, Emmanuel;Méric, Claude|
Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia
|Citation:||Vaccine 2010; 28(50): 7993-8000|
|Abstract:||Japanese encephalitis chimeric virus vaccine (JE-CV) was developed to replace licensed mouse brain-derived vaccine (MBD-JE), the production of which ceased in 2005. Two randomised controlled phase 3 studies were conducted. Immunogenicity study: 410 participants received one JE-CV injection, 410 received 3 MBD-JE injections. Safety study: 1,601 participants received JE-CV, 403 received placebo. Seroconversion after a single JE-CV vaccination (99.1%) was statistically non-inferior to that after three-dose MBD-JE (95.1%) vaccination. JE-CV elicited a rapid immune response, with 93.6% of participants seroconverting within 14 days. Adverse reaction rates were significantly lower with JE-CV (67.6%) than with MBD-JE (82.2%) (p<0.001), and the reactogenicity profile of JE-CV was comparable with that of placebo. A single dose of JE-CV elicited rapid seroconversion in a higher proportion of vaccinees than the current vaccine with fewer reactions. The safety profile of JE-CV is good.|
|Internal ID Number:||20934459|
Aged, 80 and over
Encephalitis, Japanese.prevention & control
Japanese Encephalitis Vaccines.administration & dosage.adverse effects.immunology
Vaccines, Attenuated.administration & dosage.adverse effects.immunology
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.